Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
The revenue forecast for this year has experienced a facelift, with analysts now much more optimistic on its sales pipeline. Following the latest upgrade, the 17 analysts covering Kymera Therapeutics provided consensus estimates of US$54m revenue in 2024, which would reflect a painful 31% decline on its sales over the past 12 months. Losses are supposed to balloon 37% to US$3.29 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$37m and losses of US$3.33 per share in 2024. So there's definitely been a change in sentiment in this update, with the analysts upgrading this year's revenue estimates, while at the same time holding losses per share steady. See our latest analysis for Kymera Therapeutics Analysts increased their price target 12% to US$49.86, perhaps signalling that higher revenues are a strong leading indicator for Kymera Therapeutics's valuation. One way to get more context on these forecasts is to look at how they compare
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2GlobeNewswire
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $53.00 price target on the stock.MarketBeat
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingGlobeNewswire
- Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting [Yahoo! Finance]Yahoo! Finance
KYMR
Earnings
- 2/22/24 - Beat
KYMR
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- KYMR's page on the SEC website